Non-B, non-C hepatocellular carcinoma (Review)

International Journal of Oncology

Volumn 43, Issue 5, 2013, Pages 1333-1342

  Nishikawa, Hiroki ^a   Osaki, Yukio ^a  

^a OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

Carcinogenesis; Epidemiology; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Non B; Non C hepatocellular carcinoma; Prognosis

Indexed keywords

AFLATOXIN; FERRITIN; IRON;

BUDD CHIARI SYNDROME; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHRONIC LIVER DISEASE; CLINICAL FEATURE; DIABETES MELLITUS; HEMOCHROMATOSIS; HEPATITIS NON B NON C; HUMAN; INFECTION RISK; IRON BLOOD LEVEL; IRON OVERLOAD; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; TREND STUDY; WILSON DISEASE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; LIVER NEOPLASMS; RISK FACTORS;

EID: 84885037129     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2061     Document Type: Review

References (109)

1. Livraghi T, Mäkisalo H and Line PD: Treatment options in hepatocellular carcinoma today. Scand J Surg 100: 22-29, 2011.
2. El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273, 2012.
3. De Lope CR, Tremosini S, Forner A, Reig M and Bruix J: Management of HCC. J Hepatol 56 (Suppl 1): S75-S87, 2012.
4. Nishikawa H, Osaki Y, Iguchi E, Takeda H, Matsuda F, Nakajima J, Sakamoto A, Hatamaru K, Saito S, Nasu A, Kita R and Kimura T: Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes. J Gastroenterol: Oct 12, 2012 (Epub ahead of print).
5. Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T and Osaki Y: Surgical resection for hepatocellular carcinoma: clinical outcomes and safety in elderly patients. Eur J Gastroenterol Hepatol 25: 912-919, 2013.
6. Umemura T, Ichijo T, Yoshizawa K, Tanaka E and Kiyosawa K: Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 44 (Suppl 19): 102-107, 2009.
7. Tokushige K, Hashimoto E, Horie Y, Taniai M and Higuchi S: Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol 46: 1230-1237, 2011.
8. Kaibori M, Ishizaki M, Matsui K and Kwon AH: Clinicopathologic characteristics of patients with non-B non-C hepatitis virus hepatocellular carcinoma after hepatectomy. Am J Surg 204: 300-307, 2012.
9. Abe H, Yoshizawa K, Kitahara T, Aizawa R, Matsuoka M and Aizawa Y: Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo. J Gastroenterol 43: 967-974, 2008.
10. Nagaoki Y, Hyogo H, Aikata H, Tanaka M, Naeshiro N, Nakahara T, Honda Y, Miyaki D, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S and Chayama K: Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res 42: 368-375, 2012.
11. Suzuki Y, Ohtake T, Nishiguchi S, Hashimoto E, Aoyagi Y, Onji M and Kohgo Y; The Japan Non-B, Non-C Liver Cirrhosis Study Group: Survey of non-B, non-C liver cirrhosis in Japan. Hepatol Res: Dec 26, 2012 (Epub ahead of print).
12. Kim SK, Marusawa H, Eso Y, Nishikawa H, Ueda Y, Kita R, Kimura T, Chiba T, Osaki Y and Kudo M: Clinical characteristics of non-B non-C hepatocellular carcinoma: a single-center retrospective study. Digestion 84 (Suppl 1): 43-49, 2011.
13. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L and Salizzoni M: Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123: 134-140, 2002.
14. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM and Lok AS: NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36: 1349-1354, 2002.
15. Torres DM and Harrison SA: Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin Liver Dis 32: 30-38, 2012.
16. Calle EE, Rodriguez C, Walker-Thurmond K and Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 348: 1625-1638, 2003.
17. Kaji K, Yoshiji H, Ikenaka Y, Noguchi R, Aihara Y, Shirai Y, Douhara A and Fukui H: Possible involvement of angiogenesis in chronic liver diseases: interaction among renin-angiotensin-aldosterone system, insulin resistance and oxidative stress. Curr Med Chem 19: 1889-1898, 2012.
18. Yasui K, Hashimoto E, Tokushige K, Koike K, Shima T, Kanbara Y, Saibara T, Uto H, Takami S, Kawanaka M, Komorizono Y and Okanoue T; The Japan NASH Study Group: Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. Hepatol Res 42: 767-773, 2012.
19. Chung H, Ueda T and Kudo M: Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 53: 39-43, 2010.
20. Schaefer EA and Chung RT: Anti-hepatitis C virus drugs in development. Gastroenterology 142: 1340-1350, 2012.
21. Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F and Schulz J: A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat 19 (Suppl 2): 1-26, 2012.
22. Rosen HR: Clinical practice. Chronic hepatitis C infection. N Engl J Med 364: 2429-2438, 2011.
23. Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK and Canbay A: Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 128: 2436-2443, 2011.
24. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C, Porru S and Nardi G: Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 155: 323-331, 2002.
25. Corrao G, Bagnardi V, Zambon A and La Vecchia C: A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med 38: 613-619, 2004.
26. Sookoian S and Pirola CJ: The genetic epidemiology of nonalcoholic fatty liver disease: toward a personalized medicine. Clin Liver Dis 16: 467-485, 2012.
27. Shen L, Fan JG, Shao Y, Zeng MD, Wang JR, Luo GH, Li JQ and Chen SY: Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 9: 1106-1110, 2003.
28. Ong JP and Younossi ZM: Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 11: 1-16, 2007.
29. Kojima S, Watanabe N, Numata M, Ogawa T and Matsuzaki S: Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 38: 954-961, 2003.
30. Harrison SA, Torgerson S and Hayashi PH: The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 98: 2042-2047, 2003.
31. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW and Powell LW: The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11: 74-80, 1990.
32. Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K and Shiratori K: Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 44 (Suppl 19): 89-95, 2009.
33. Hashizume H, Sato K, Takagi H, Hirokawa T, Kojima A, Sohara N, Kakizaki S, Mochida Y, Shimura T and Sunose Y: Primary liver cancers with nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol 19: 827-834, 2007.
34. Yoshioka Y, Hashimoto E, Yatsuji S, Kaneda H, Taniai M, Tokushige K and Shiratori K: Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH. J Gastroenterol 39: 1215-1218, 2004.
35. Ayata G, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL and Khettry U: Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol 33: 1098-1104, 2002.
36. Starley BQ, Calcagno CJ and Harrison SA: Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51: 1820-1832, 2010.
37. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF and Zein NN: The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51: 1972-1978, 2010.
38. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K and Shiratori K: Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 24: 248-254, 2009.
39. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA and McGlynn KA: Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 54: 463-471, 2011.
40. El-Serag HB, Tran T and Everhart JE: Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126: 460-468, 2004.
41. Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, Li G and Wang L: Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer 130: 1639-1648, 2012.
42. Neuschwander-Tetri BA and Caldwell SH: Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37: 1202-1219, 2003.
43. Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA and Maldonado-Garza H: Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 15: 280-288, 2009.
44. Allison ME, Wreghitt T, Palmer CR and Alexander GJ: Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 21: 1135-1139, 1994.
45. El-Serag HB, Johnson ML, Hachem C and Morgana RO: Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 136: 1601-1608, 2009.
46. Ohata K, Hamasaki K, Toriyama K, Matsumoto K, Saeki A, Yanagi K, Abiru S, Nakagawa Y, Shigeno M, Miyazoe S, Ichikawa T, Ishikawa H, Nakao K and Eguchi K: Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 97: 3036-3043, 2003.
47. Shimizu M, Tanaka T and Moriwaki H: Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. Semin Immunopathol 35: 191-202, 2013.
48. Bianchini F, Kaaks R and Vainio H: Overweight, obesity, and cancer risk. Lancet Oncol 3: 565-574, 2002.
49. Larsson SC and Wolk A: Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 97: 1005-1008, 2007.
50. Moller H, Mellemgaard A, Lindvig K and Olsen JH: Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 30A: 344-350, 1994.
51. Oh SW, Yoon YS and Shin SA: Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 23: 4742-4754, 2005.
52. Drakesmith H and Prentice A: Viral infection and iron metabolism. Nat Rev Microbiol 6: 541-552, 2008.
53. Sorrentino P, D'Angelo S, Ferbo U, Micheli P, Bracigliano A and Vecchione R: Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol 50: 351-357, 2009.
54. Ioannou GN, Weiss NS and Kowdley KV: Relationship between transferrin-iron saturation, alcohol consumption, and the incidence of cirrhosis and liver cancer. Clin Gastroenterol Hepatol 5: 624-629, 2007.
55. Harada K, Hirohara J, Ueno Y, Nakano T, Kakuda Y, Tsubouchi H, Ichida T and Nakanuma Y: Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan. Hepatology 57: 1942-1949, 2013.
56. Migita K, Watanabe Y, Jiuchi Y, Nakamura Y, Saito A, Yagura M, Ohta H, Shimada M, Mita E, Hijioka T, Yamashita H, Takezaki E, Muro T, Sakai H, Nakamuta M, Abiru S, Komori A, Ito M, Yatsuhashi H, Nakamura M and Ishibashi H; Japanese NHO-Liver-network study group: Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study). Liver Int 32: 837-844, 2012.
57. Harnois DM, Gores JG, Ludwig J, Steers JL, LaRusso NE and Wiesner RH: Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? J Hepatol 27: 512-516, 1997.
58. Razumilava N, Gores GJ and Lindor KD: Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 54: 1842-1852, 2011.
59. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH and Kushner JP: Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 318: 1355-1362, 1988.
60. Powell LW, Subramaniam VN and Yapp TR: Haemochromatosis in the new millennium. J Hepatol 32: 48-62, 2000.
61. Hsing AW, McLaughlin JK, Olsen JH, Mellemkjar L, Wacholder S and Fraumeni JF Jr: Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer 60: 160-162, 1995.
62. Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A and Fargion S: Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 33: 647-651, 2001.
63. Yang Q, McDonnell SM, Khoury MJ, Cono J and Parrish RG: Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of multiple-cause mortality data. Ann Intern Med 129: 946-953, 1998.
64. Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, Olsson R, Lindgren S, Lööf L, Stål P, Wallerstedt S, Almer S, Sandberg- Gertzén H and Askling J: Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 125: 1733-1741, 2003.
65. Wang Y, Xie CL, Fu DL, Lu L, Lin Y, Dong QQ, Wang XT and Zheng GQ: Clinical efficacy and safety of Chinese herbal medicine for Wilson's disease: a systematic review of 9 randomized controlled trials. Complement Ther Med 20: 143-154, 2012.
66. Michitaka K, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y and Onji M; Japan Etiology of Liver Cirrhosis Study Group: Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol 45: 86-94, 2010.
67. Tanaka M and Wanless IR: Pathology of the liver in Budd-Chiari syndrome: portal vein thrombosis and the histogenesis of veno-centric cirrhosis, veno-portal cirrhosis, and large regenerative nodules. Hepatology 27: 488-496, 1998.
68. Okuda K: Inferior vena cava thrombosis at its hepatic portion (obliterative hepatocavopathy). Semin Liver Dis 22: 15-26, 2002.
69. Ren W, Qi X, Yang Z, Han G and Fan D: Prevalence and risk factors of hepatocellular carcinoma in Budd-Chiari syndrome: a systematic review. Eur J Gastroenterol Hepatol 25: 830-841, 2013.
70. Raimondo G, Pollicino T, Cacciola I and Squadrito G: Occult hepatitis B virus infection. J Hepatol 46: 160-170, 2007.
71. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR and Zoulim F: Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49: 652-657, 2008.
72. Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T and Osaki Y: Lack of correlation between the antibody to hepatitis B core antigen and survival after surgical resection for hepatitis C virus-related hepatocellular carcinoma. Oncol Rep 30: 91-98, 2013.
73. Raimondo G, Caccamo G, Filomia R and Pollicino T: Occult HBV infection. Semin Immunopathol 35: 39-52, 2013.
74. Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, Restuccia T, Cucinotta E, Scisca C, Magazzu D and Raimondo G: Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 106: 1326-1330, 2006.
75. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E and Raimondo G: Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 126: 102-110, 2004.
76. Wu HC and Santella R: The role of aflatoxins in hepatocellular carcinoma. Hepat Mon 12: e7238, 2012.
77. Chen CJ, Wang LY, Lu SN, Wu MH, You SL, Zhang YJ, Wang LW and Santella RM: Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology 24: 38-42, 1996.
78. Kawaguchi T, Izumi N, Charlton MR and Sata M: Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology 54: 1063-1070, 2011.
79. Price JA, Kovach SJ, Johnson T, Koniaris LG, Cahill PA, Sitzmann JV and McKillop IH: Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma. Hepatology 36: 1089-1097, 2002.
80. Buzzelli G, Dattolo P, Pinzani M, Brocchi A, Romano S and Gentilini P: Circulating growth hormone and insulin-like growth factor-I in nonalcoholic liver cirrhosis with or without superimposed hepatocarcinoma: evidence of an altered circadian rhythm. Am J Gastroenterol 88: 1744-1748, 1993.
81. Kasprzak A and Adamek A: The insulin-like growth factor (IGF) signaling axis and hepatitis C virus-associated carcinogenesis (Review). Int J Oncol 41: 1919-1931, 2012.
82. Shimizu M, Kubota M, Tanaka T and Moriwaki H: Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis. Int J Mol Sci 13: 579-595, 2012.
83. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, Karin M and Hotamisligil GS: A central role for JNK in obesity and insulin resistance. Nature 420: 333-336, 2002.
84. Puri P, Mirshahi F, Cheung O, Natarajan R, Maher JW, Kellum JM and Sanyal AJ: Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 134: 568-576, 2008.
85. Duan XF, Tang P, Li Q and Yu ZT: Obesity, adipokines and hepatocellular carcinoma. Int J Cancer: Feb 12, 2013 (Epub ahead of print).
86. Asano T, Watanabe K, Kubota N, Gunji T, Omata M, Kadowaki T and Ohnishi S: Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J Gastroenterol Hepatol 24: 1669-1676, 2009.
87. Brakenhielm E, Veitonmäki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, Funahashi T and Cao Y: Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 101: 2476-2481, 2004.
88. Kitade M, Yoshiji H, Kojima H, Ikenaka Y, Noguchi R, Kaji K, Yoshii J, Yanase K, Namisaki T and Asada K: Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 44: 983-991, 2006.
89. Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, Lang T, Fukuda T, Yamashina S, Kitamura T and Sato N: Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 122: 1399-1410, 2002.
90. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231, 2002.
91. Yang S, Zhu H, Li Y, Lin H, Gabrielson K, Trush MA and Diehl AM: Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 378: 259-268, 2000.
92. Nowsheen S, Aziz K, Kryston TB, Ferguson NF and Georgakilas A: The interplay between inflammation and oxidative stress in carcinogenesis. Curr Mol Med 12: 672-680, 2012.
93. Marnett LJ: Oxyradicals and DNA damage. Carcinogenesis 21: 361-370, 2000.
94. Petta S and Craxì A: Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association. Curr Pharm Des 16: 741-752, 2010.
95. Ishii H, Horie Y, Ohshima S, Anezaki Y, Kinoshita N, Dohmen T, Kataoka E, Sato W, Goto T and Sasaki J: Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice. J Hepatol 50: 562-571, 2009.
96. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P and Poynard T: Liver fibrosis in overweight patients. Gastroenterology 118: 1117-1123, 2000.
97. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R and Ruggiero G: Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33: 1358-1364, 2001.
98. Westin J, Nordlinder H, Lagging M, Norkrans G and Wejstal R: Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 37: 837-842, 2002.
99. Takuma Y and Nouso K: Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol 16: 1436-1441, 2010.
100. Duan XY, Qiao L and Fan JG: Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 11: 18-27, 2012.
101. Reddy SK, Steel JL, Chen HW, DeMateo DJ, Cardinal J, Behari J, Humar A, Marsh JW, Geller DA and Tsung A: Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 55: 1809-1819, 2012.
102. Li T, Qin LX, Gong X, Zhou J, Sun HC, Qiu SJ, Ye QH, Wang L and Fan J: Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection. Cancer 119: 126-135, 2013.
103. Malik SM, Gupte PA, de Vera ME and Ahmad J: Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. Clin Gastroenterol Hepatol 7: 800-806, 2009.
104. Giannini EG, Marabotto E, Savarino V, Trevisani F, di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M and Borzio F: Hepatocellular carcinoma in patients with cryptogenic cirrhosis. Clin Gastroenterol Hepatol 7: 580-585, 2009.
105. Tokushige K, Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N and Shiratori K: Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol 45: 960-967, 2010.
106. Kusakabe A, Tanaka Y, Orito E, Sugauchi F, Kurbanov F, Sakamoto T, Shinkai N, Hirashima N, Hasegawa I, Ohno T, Ueda R and Mizokami M: A weak association between occult HBV infection and non-B non-C hepatocellular carcinoma in Japan. J Gastroenterol 42: 298-305, 2007.
107. Hatanaka K, Kudo M, Fukunaga T, Ueshima K, Chung H, Minami Y, Sakaguchi Y, Hagiwara S, Orino A and Osaki Y: Clinical characteristics of nonBnonC-HCC: comparison with HBV and HCV related HCC. Intervirology 50: 24-31, 2007.
108. Nishikawa H, Osaki Y, Takeda H, Sakamoto A, Saito S, Nishijima N, Nasu A, Arimoto A, Kita R and Kimura T: Effect of body mass index on survival after curative therapy for non-B non-C hepatocellular carcinoma. J Gastrointestin Liver Dis 22: 173-181, 2013.
109. Cauchy F, Zalinski S, Dokmak S, Fuks D, Farges O, Castera L, Paradis V and Belghiti J: Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome. Br J Surg 100: 113-121, 2013.